MedTrace Logo

Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib

NCT01352728 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-06-20

No results posted yet for this study

Summary

The survival of subjects with unresectable hepatocellular carcinoma (HCC) receiving transarterial chemoembolization is improved with addition of axitinib.

Conditions

Interventions

DRUG

Axitinib

5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Stephen L Chan, MRCP · Chinese University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-18
Primary Completion
2018-06-07
Completion
2018-06-07

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01352728 on ClinicalTrials.gov